Project Group Dr. Dorothee von Laer

Research Focus

Oncolytic viruses: The vesicular stomatitis virus (VSV) is a highly potent cancer destroying (oncolytic) virus, but neurotoxicity has limited its clinical application in the past. We are currently developing highly potent but less neurotoxic oncoloytic VSV variants by exchanging the envelope glycoprotein (VSV-GP) and/or distributing the viral genes onto two viral genomes (complementary replicating VSV). A spin-off of Innsbruck Medical University - ViraTherapeutics GmbH - will take the lead in the further development of VSV-GP. First-in-man clinical trials are exptected in three years. (Houskapreis 2013).

Gene therapy of HIV infection: In the past years we developed a novel antiviral gene that efficiently inhibits HIV infection at the level of cell entry. This serves as the basis of a novel gene therapy strategy for HIV infection, which is currently tested in a clinical trial.


  • Dorothee von Laer, Gruppenleiterin, (Curriculum Vitae)
  • Lisa Pipperger, M.Sc., PhD student
  • Andre Volland, M.Sc., PhD student
  • Emmanuel Heilmann, M.Sc., PhD student
  • Annika Rössler, M.Sc., PhD student
  • Albert Falch, M.Sc., Technical Assistent

Publikationen (Link pubmed)